PROLIFERATING CELL NUCLEAR ANTIGEN AND NUCLEOLAR ORGANIZER REGIONS INCNS TUMORS - CORRELATION WITH HISTOLOGICAL TYPE AND TUMOR GRADE - A COMPARATIVE-STUDY OF 82 CASES ON PARAFFIN SECTIONS
P. Korkolopoulou et al., PROLIFERATING CELL NUCLEAR ANTIGEN AND NUCLEOLAR ORGANIZER REGIONS INCNS TUMORS - CORRELATION WITH HISTOLOGICAL TYPE AND TUMOR GRADE - A COMPARATIVE-STUDY OF 82 CASES ON PARAFFIN SECTIONS, The American journal of surgical pathology, 17(9), 1993, pp. 912-919
We investigated the expression of proliferating cell nuclear antigen (
PCNA) and the number of nucleolar organizer regions (NORs) in 82 cases
of CNS tumors. PCNA is a nuclear protein maximally elevated in the S
phase of the cell cycle and recognized immunohistochemically in paraff
in sections by the monoclonal antibody PC-10. On the other hand, NORs
are loops of DNA that carry the rRNA genes and can be demonstrated in
paraffin sections using an argyrophilic method (AgNORs). The present s
tudy shows a significant correlation of PCNA index and of AgNOR number
with the histological grade (PCNA: I versus II, p < 0.01; II versus I
II, p < 0.01; and III versus IV, p < 0.05; AgNORs: I versus II, p < 0.
001; II versus III, p < 0.05- and III versus IV, p < 0.001). Higher va
lues of PCNA index (0.01 < p < 0.05) were found in recurrent tumors. M
etastatic carcinomas were characterized by high PCNA indices and AgNOR
numbers, similar to grade IV tumors, whereas in CNS lymphomas the mal
ignancy grade was reflected in PCNA indices and AgNOR numbers. A wide
range of PCNA and AgNOR values has been observed within each histologi
cal type and grade, probably reflecting variations in the biological b
ehavior, but little overlap in PCNA values was present between grades
II and III. The latter finding might be of importance in distinguishin
g between low- and high-grade CNS tumors. The linear regression coeffi
cient between PCNA index and AgNOR number was excellent (0.91). We sug
gest that PCNA and AgNORs may be successfully applied in routine mater
ial to assess the growth potential of CNS tumors. Their prognostic val
ue, however, must be validated with clinical studies.